000			03191nam a22003617a 4500
008			240723s20232023 xxu||||| |||| 00| 0 eng d
024			_aPMC10705686 [pmc]
040			_aOvid MEDLINE(R)
099			_a38076963
245			_aIliocaval and Iliofemoral Venous Stenting for Obstruction Secondary to Tumor Compression: Single Center Experience.
251			_aResearch Square. 2023 Nov 28
252			_aRes Sq. 2023 Nov 28
253			_aResearch square
260			_c2023
260			_p2023 Nov 28
260			_fFY2024
265			_sepublish
265			_tPubMed-not-MEDLINE
520			_aBackground: Cancer patients with pelviabdominal masses can suffer from lower extremity symptoms due to venous compression. The effectiveness of venous stenting has been established in extrinsic venous compression in benign conditions like May-Thurner syndrome. In this retrospective study we evaluate the efficacy and safety of caval, iliocaval and iliofemoral venous stenting for cases of extrinsic venous compression caused by malignant masses in cancer patients.
520			_aConclusion: Venous stenting is a safe procedure and should be considered as part of the palliative care for patients with debilitating lower extremity symptoms related to iliocaval and iliofemoral venous compression.
520			_aMethods: IRB-approved retrospective review of patients who underwent iliofemoral venography with venoplasty and stenting between January 2018 and February 2022 was performed. Patients with extrinsic venous compression caused by malignant masses were included. Data on patient demographics, pre-procedure symptoms, procedural technique, stent characteristics, outcomes and follow-up were collected. Descriptive statistics were used to assess technical success, clinical success, primary stent patency and adverse events of the procedure.
520			_aResults: Thirty-seven patients (19 males, 18 females) who underwent 45 procedures were included. Deep venous thrombosis (DVT) was present in 21 (57%) patients. Twenty-nine patients (78%, 95% CI 62-90%) reported clinical improvement of the presenting symptoms. The median overall survival after the procedure was 4.7 months (95% CI 3.58-5.99). Eight (22%) patients were alive at last follow up with median follow up of 10.33 months (Range 2-25 months). Twenty-six patients had patent stents on their last follow up imaging (70%, 95% CI 61%-91%). Two patients had a small access site hematoma which resolved spontaneously. Two patients developed moderate, and 1 patient developed severe adverse events related to post procedure therapeutic anticoagulation.
546			_aEnglish
650			_zAutomated
651			_aMedStar Washington Hospital Center
656			_aRadiology
657			_aPreprint
700			_aAly, Ahmed K _bMWHC
790			_aAly AK, Moussa A, Chevallier O, Kishore S, Petre E, Friedman A, Bryce Y, Gonzalez-Aguirre A, Camacho J, Santos E, Ridouani F
856			_uhttps://dx.doi.org/10.21203/rs.3.rs-3588250/v1 _zhttps://dx.doi.org/10.21203/rs.3.rs-3588250/v1
858			_yAly, Ahmed K _uhttps://orcid.org/0000-0002-1050-3205 _zhttps://orcid.org/0000-0002-1050-3205
942			_cART _dArticle
999			_c14259 _d14259